Abstract

ABSTRACT:
BACKGROUND:
Since long time, unfractionated heparin has been used as standard anticoagulant
for percutaneous coronary intervention(PCI).however, recently several studies showed that intravenous
enoxaparin safety and effectiveness is similar to that of unfractionated heparin.
OBJECTIVE :
To assess the safety and practicity of enoxaparin compared with un fractionated heparin in elective PCI
using drug eluting stents (DES).
METHODS:
In this prospective, randomized trial, at the cardiac unit of Ashty hospital in Erbil city, from July 2014
to February 2016, we included 300 patients undergoing elective PCI. 150 patient received enoxaparin
0.6 mg per kilogram of body weight, the other 150 patient received unfractionated heparin 100 u per
kilogram of body weight adjusted for activated clotting time.
The primary end point is the incidence of bleeding (minor or major). While the mortality and the
incidence of acute coronary events within 24 hours after PCI was the secondary end point.
RESULTS:
There was reduction, however statistically insignificant (p value>0.05) in the rate of major and minor
bleeding in Enoxaparin group in the first 24 hours as compared with unfractionated heparin (4 % vs.
5.25%; absolute difference –1.25).The acute coronary events and death rate was similar.
CONCLUSION:
In elective PCI using DES, a single intravenous bolus of Enoxaparin at a dose of 0.6 mg per kilogram
was at least as safe as effective as unfractionated heparin with simpler use and faster indwelling sheath
removal.
.